Literature DB >> 24445215

Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.

Stuart McPherson1, Elsbeth Henderson2, Alastair D Burt3, Christopher P Day4, Quentin M Anstee4.   

Abstract

BACKGROUND & AIMS: A third of the population are estimated to have NAFLD of varying severity. Serum immunoglobulins are frequently elevated in patients with chronic liver disease, but little is known about serum immunoglobulin levels in patients with NAFLD. Aim of this study was to evaluate serum immunoglobulin levels (IgA, IgG, and IgM) in a large cohort of patients with biopsy-proven NAFLD and determine if immunoglobulin levels are associated with clinical or histological features.
METHODS: Patients seen in a tertiary fatty liver clinic between 1999 and 2009 were included. Liver biopsies were assessed using the Kleiner score. Immunoglobulin levels and other blood tests were taken at time of biopsy.
RESULTS: 285 patients (110 simple steatosis and 175 NASH) had serum immunoglobulins measured within 6months of liver biopsy. 130 (46%) patients had elevated (>1× upper limit of normal) serum IgA levels, 28 (10%) patients had elevated IgG and 22 (8%) raised IgM. Serum IgA levels were elevated more frequently in patients with NASH compared with subjects with simple steatosis (55% vs. 31%, p<0.001). Overall, 55 (19%) patients had advanced liver fibrosis (Kleiner stage 3-4). There was a significant positive association between serum IgA levels and the stage of fibrosis (p<0.001). Serum IgA, age, platelets, AST/ALT ratio and BMI were all independently with advanced fibrosis following multivariate analysis. A model constructed from these independent predictors accurately predicted advanced fibrosis (AUROC 0.87).
CONCLUSIONS: The serum IgA level was frequently elevated in patients with NAFLD and was an independent predictor of advanced fibrosis.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetes; Fatty liver; Fibrosis; IgA; IgG; Immunoglobulins; NASH; Steatohepatitis

Mesh:

Substances:

Year:  2014        PMID: 24445215     DOI: 10.1016/j.jhep.2014.01.010

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  33 in total

1.  Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.

Authors:  Noriyuki Koyama; Tomoko Yamazaki; Yuka Kanetsuki; Jiro Hirota; Tomohide Asai; Yasuhide Mitsumoto; Masayuki Mizuno; Toshihide Shima; Yoshihiro Kanbara; Satoko Arai; Toru Miyazaki; Takeshi Okanoue
Journal:  J Gastroenterol       Date:  2017-10-30       Impact factor: 7.527

Review 2.  Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH).

Authors:  Xiaohan Xu; Kyle L Poulsen; Lijuan Wu; Shan Liu; Tatsunori Miyata; Qiaoling Song; Qingda Wei; Chenyang Zhao; Chunhua Lin; Jinbo Yang
Journal:  Signal Transduct Target Ther       Date:  2022-08-13

3.  Serum immunoglobulin A levels and non-alcoholic fatty liver disease.

Authors:  Evan Elias; Julia Uhanova; Qian Li; Manna Zhang; Gerald Minuk
Journal:  Can Liver J       Date:  2018-12-25

4.  Serum Immunoglobulin A Levels Do Not Correlate With Liver Disease Severity in Pediatric Nonalcoholic Fatty Liver Disease.

Authors:  Marialena Mouzaki; Kristin Bramlage; Ana Catalina Arce-Clachar; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-11       Impact factor: 2.839

5.  Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.

Authors:  E Muchtar; A Dispenzieri; S K Kumar; F K Buadi; M Q Lacy; S Zeldenrust; S R Hayman; N Leung; T V Kourelis; W Gonsalves; R Chakraborty; S Russell; D Dingli; J A Lust; Y Lin; P Kapoor; R Go; R A Kyle; S V Rajkumar; M A Gertz
Journal:  Leukemia       Date:  2016-05-23       Impact factor: 11.528

Review 6.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

7.  Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity.

Authors:  Shabnam Shalapour; Xue-Jia Lin; Ingmar N Bastian; John Brain; Alastair D Burt; Alexander A Aksenov; Alison F Vrbanac; Weihua Li; Andres Perkins; Takaji Matsutani; Zhenyu Zhong; Debanjan Dhar; Jose A Navas-Molina; Jun Xu; Rohit Loomba; Michael Downes; Ruth T Yu; Ronald M Evans; Pieter C Dorrestein; Rob Knight; Christopher Benner; Quentin M Anstee; Michael Karin
Journal:  Nature       Date:  2017-11-08       Impact factor: 49.962

Review 8.  Cell death and cell death responses in liver disease: mechanisms and clinical relevance.

Authors:  Tom Luedde; Neil Kaplowitz; Robert F Schwabe
Journal:  Gastroenterology       Date:  2014-07-18       Impact factor: 22.682

Review 9.  Metformin Actions on the Liver: Protection Mechanisms Emerging in Hepatocytes and Immune Cells against NASH-Related HCC.

Authors:  Yueqi Zhang; Hongbing Wang; Hua Xiao
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

Review 10.  The neglected brothers come of age: B cells and cancer.

Authors:  Shabnam Shalapour; Michael Karin
Journal:  Semin Immunol       Date:  2021-06-29       Impact factor: 10.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.